Close Menu

Biocept

The CTC-based oncology diagnostics firm raised $15.6 million in net proceeds from a public offering of its securities in February. 

The firm saw its revenues more than quadruple year over year to $150,000, mainly due to expansion of its commercial liquid biopsy testing business.

The partners hope to demonstrate the clinical utility of Biocept's liquid biopsy technology in improving the care of NSCLC patients.

In 2014 the firm launched a new lung cancer liquid biopsy test and hired a sales and marketing team. The firm also saw a large increase in R&D costs.

The firm said in an SEC document that it plans to offer up to $11.5 million in its common shares and up to $11.5 million in common stock issuable upon the exercise of warrants.

The deal centers around ALK, a gene involved in signal transduction and a therapeutic target for non-small cell lung cancer.

The non-invasive, blood-based circulating tumor cell and circulating tumor DNA cancer tests will be made available to 19 million patients. 

The company launched a blood-based diagnostic to guide treatment strategies for lung cancer patients with ALK fusions who don't have sufficient tumor biopsy material for analysis by tissue-based tests.

NEW YORK (GenomeWeb) – Biocept reported today that its third quarter net loss increased 34 percent year over year, as the firm expanded initiatives in its fledgling oncology diagnostics business.

NEW YORK (GenomeWeb) — Biocept and Rosetta Genomics said this week that they will pair Biocept's circulating tumor cell isolation technology with Rosetta's microRNA analysis platforms to investigate the possibility of developing blood-based cancer diagnostics and therapeutic response assays.

Pages

A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.

Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.

Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.

In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.